EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes

Zsolt Szekeres, Barbara Sandor, Zita Bognar iD, Fadi H J Ramadan iD, Anita Palfi, Beata Bodis iD, Kalman Toth iD, Eszter Szabados iD

International Journal of Molecular Sciences · 23.02.2023 · 24 (5) · 4405

DOI: 10.3390/ijms24054405 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.02.2023. Verfasst von Zsolt Szekeres und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Preventive Cardiology and Rehabilitation, 1st Department of Medicine, Medical School, University of Pecs, 7624 Pecs, Hungary. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Pecs, Medical School, Hungary, János Bolyai Research Scholarship of the Hungarian Academy of Sciences, National Research, Development and Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity is a major public health problem worldwide, and it is associated with many diseases and abnormalities, most importantly, type 2 diabetes. The visceral adipose tissue produces an immense variety of adipokines. Leptin is the first identified adipokine which plays a crucial role in the regulation of food intake and metabolism. Sodium glucose co-transport 2 inhibitors are potent antihyperglycemic drugs with various beneficial systemic effects. We aimed to investigate the metabolic state and leptin level among patients with obesity and type 2 diabetes mellitus, and the effect of empagliflozin upon these parameters. We recruited 102 patients into our clinical study, then we performed anthropometric, laboratory, and immunoassay tests. Body mass index, body fat, visceral fat, urea nitrogen, creatinine, and leptin levels were significantly lower in the empagliflozin treated group when compared to obese and diabetic patients receiving conventional antidiabetic treatments. Interestingly, leptin was increased not only among obese patients but in type 2 diabetic patients as well. Body mass index, body fat, and visceral fat percentages were lower, and renal function was preserved in patients receiving empagliflozin treatment. In addition to the known beneficial effects of empagliflozin regarding the cardio-metabolic and renal systems, it may also influence leptin resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsHumansLeptinObesityHypoglycemic AgentsBenzhydryl CompoundsAdipokinesGlucosides

Stichwörter der Autor:innen

empagliflozinleptinlipid metabolismobesitytype 2 diabetes mellitus

Substanzen

Sodium-Glucose Transporter 2 InhibitorsLeptinHypoglycemic AgentsBenzhydryl CompoundsAdipokinesempagliflozinGlucosides

Autor:innen und Institutionen

  • Division of Preventive Cardiology and Rehabilitation, 1st Department of Medicine, Medical School, University of Pecs, 7624 Pecs, Hungary.
  • Department of Biochemistry and Medical Chemistry, University of Pecs, Medical School, 7624 Pecs, Hungary.
  • Division of Endocrinology and Metabolism, 1st Department of Medicine, Medical School, University of Pecs, 7624 Pecs, Hungary.
  • Division of Cardiology, 1st Department of Medicine, Medical School, University of Pecs, 7624 Pecs, Hungary.

ORCID-Profile: Zita Bognar, Fadi H J Ramadan, Beata Bodis, Kalman Toth, Eszter Szabados

Förderung

  • University of Pecs, Medical School, Hungary
  • János Bolyai Research Scholarship of the Hungarian Academy of Sciences
  • National Research, Development and Innovation
  • Hungarian Ministry for Innovation and Technology

Zitieren

APA

Szekeres, Z., Sandor, B., Bognar, Z., Ramadan, F. H. J., Palfi, A., Bodis, B., Toth, K., & Szabados, E. (2023). Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes. International Journal of Molecular Sciences, 24(5), 4405. https://doi.org/10.3390/ijms24054405

Vancouver

Szekeres Z, Sandor B, Bognar Z, Ramadan FHJ, Palfi A, Bodis B, et al. Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes. International Journal of Molecular Sciences. 2023;24(5):4405. doi:10.3390/ijms24054405

BibTeX
@article{Szekeres2023,
  author = {Szekeres, Zsolt and Sandor, Barbara and Bognar, Zita and Ramadan, Fadi H J and Palfi, Anita and Bodis, Beata and Toth, Kalman and Szabados, Eszter},
  title = {Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {5},
  pages = {4405},
  doi = {10.3390/ijms24054405}
}
Kostenlos starten →